Lead MitoXcel™ geropeptide candidate designed to restore mitochondrial bioenergetics (ΔΨm) and reduce senescent-cell inflammatory burden to improve physical function and body composition in older adults.
MitoXcel™ Technology PlatformPTC-2105 for Sarcopenia & Sarcopenic Obesity
Program Overview
Best-in-class ΔΨm-targeted gerotherapeutic for age-related loss of muscle mass and function.
- Indications: Sarcopenia and Sarcopenic Obesity
- Population: Older adults (≥ 60 years)
- Rationale: Aging and senescent cells exhibit reduced mitochondrial membrane potential (ΔΨm); restoring ΔΨm and removing senescent cells addresses upstream drivers of functional decline.
- Primary endpoints: Physical function improvement; favorable body composition (↓ fat, ↑ muscle)
Patient Need
Sarcopenia leads to loss of independence, increased falls, morbidity and mortality. In sarcopenic obesity, excess adiposity compounds disability risk. GLP-1-based pharmacotherapy can exacerbate lean mass loss, raising concerns for these patients.
- Loss of independence and increased healthcare utilization
- Higher risk of fractures, disability, and mortality
- Complex co-morbid profile in sarcopenic obesity
Mechanism of Action
A single target, the Mitochondrial Membrane Potential (ΔΨm). Two synergistic, mitochondrial-mediated effects.
- ΔΨm Restoration in Aging Cells: Rapid improvement in mitochondrial efficiency, moving cells toward a youthful energetic phenotype.
- Selective Senescent Cell Apoptosis: Cells unable to restore ΔΨm—predominantly senescent cells—undergo apoptosis, reducing SASP cytokines (e.g., IL-6, TNF-α) and enabling muscle regeneration.
Preclinical studies have shown robust tissue-wide effects without observed adverse events (illustrative summary).
Preclinical Evidence
Reduction in Systemic Inflammation
- System-wide senescent cell reduction via apoptosis
- Reduction of the senescence-associated secretory phenotype (SASP) in the plasma.
Improvement in Body Composition
- Increased loss of fat compared to GLP-1 and control
- Improved muscle regeneration and body composition
- Preferential loss of abdominal/visceral fat compared to overall fat
- No observed adverse effects in studies to date
Dramatic Physical Function Benefit
- Rapid improvement in mitochondrial efficiency of aging cells
- Enhanced physical function metrics in aged animals
- No observed adverse effects in studies to date
Full datasets and protocols available under CDA.
Clinical Development Plan
Endpoints and eligibility aligned to functional benefit and body composition.
Key Eligibility
- Age ≥ 60
- Sarcopenia or sarcopenic obesity diagnosis
- GLP-1 agonist therapy not appropriate / contraindicated
Primary Endpoints
- Body composition improvement (loss of fat, gain of muscle)
- Physical function benefit (e.g., gait speed, 5xSTS, SPPB)
To be finalized per protocol and regulatory guidance.
